Sugi Predict

Sugi Predict / Compounds / SCHEMBL558081

SCHEMBL558081

SCHEMBL558081

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cc(Cl)ncn1

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.38
▸ SYK P43405 1/20 0.37
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ AAK1 Q2M2I8 3/20 0.34
▸ ATR Q13535 1/20 0.33
▸ GRM5 P41594 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ USP30 Q70CQ3 1/20 0.31
▸ FGFR4 P22455 1/20 0.31
▸ TRPA1 O75762 1/20 0.31
▸ MT-CO2 P00403 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29400643 1.00 PDPK1 (0.38) PDPK1SYKLMNAKMT2AAAK1
SCHEMBL3592339 0.86 GRM5 (0.36) PDPK1LMNAKMT2AAAK1ATR
SCHEMBL3804334 0.85 GRM5 (0.33) PDPK1LMNAKMT2AAAK1ATR
SCHEMBL23025029 0.81 SSTR4 (0.36) PDPK1SYKAAK1USP30
SCHEMBL15274739 0.81 PDPK1 (0.40) PDPK1SYKMAP4K4USP30
SCHEMBL14017748 0.79 MT-CO2 (0.39) MT-CO2
SCHEMBL29070858 0.79 JAK3 (0.40) PDPK1SYK
SCHEMBL8819730 0.79 PDPK1 (0.35) PDPK1SYKUSP30FGFR4
SCHEMBL30855200 0.79 PDPK1 (0.35) PDPK1SYKUSP30
SCHEMBL6107019 0.79 GRM5 (0.34) GRM5FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3521289-B1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
EP-3521289-B1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
CN-116490505-A MNK inhibitors 和博医药有限公司 2023-07-25 — — CN disclosed
CN-110183449-B Mnk inhibitors and methods related thereto 效应治疗股份有限公司 2022-08-19 — — CN disclosed
US-20210338673-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2021-11-04 — — US disclosed
US-20210338673-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2021-11-04 — — US disclosed
EP-2985283-B1 ANTI-ANGIOGENESIS COMPOUND, INTERMEDIATE AND USE THEREOF GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECH CO LTD (CN) 2021-10-06 — — EP disclosed
EP-3521289-A1 MNK INHIBITORS AND METHODS RELATED THERETO Effector Therapeutics Inc. (US) 2019-08-07 — — EP disclosed
EP-3521289-A1 MNK INHIBITORS AND METHODS RELATED THERETO Effector Therapeutics Inc. (US) 2019-08-07 — — EP disclosed
US-20190209560-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. 2019-07-11 — — US disclosed
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 — — US disclosed
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 — — US disclosed
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 — — US disclosed
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 — — US disclosed
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 — — US disclosed
WO-2011053292-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-05 — — WO disclosed
WO-2011053292-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-05 — — WO disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 — — US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 — — US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 PDPK1 1859/4885SYK 4005/4885LMNA 2215/4885
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 PDPK1 1859/4885SYK 4005/4885LMNA 2215/4885
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 PDPK1 1859/4885SYK 4005/4885LMNA 2215/4885
US-20190209560-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 PDPK1 268/4885SYK 1400/4885LMNA 1093/4885
US-20210338673-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 PDPK1 268/4885SYK 1400/4885LMNA 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.